🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the infection, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with figures suggesting over 82 million instances each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This infection can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the drugmaker GSK, also received approval in close succession. This medication, which is employed against UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the management of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Data and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the current standard treatment, which involves a dual-drug approach. The study enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in many developing nations.

Medical professionals directly involved have voiced positive views. Having a single-dose, oral treatment such as this is seen as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the disease for patients and to stop the proliferation of untreatable gonorrhoea globally.